Krzysztof Czyzewski1, Robert Debski1, Anna Krenska1, Mariusz Wysocki1, Jan Styczynski2. 1. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 2. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland jstyczynski@cm.umk.pl.
Abstract
BACKGROUND: Keratinocyte growth factor (palifermin) is used for prevention of mucositis in adults following autologous and allogeneic hematopoietic stem cell transplantation (HSCT). It is known that palifermin decreases length of initial hospital stay, mean number of days of total parenteral nutrition (TPN) and the use of opioids for pain control in oral mucositis in adults. There are limited data evaluating palifermin use in children following autologous HSCT. AIM: The objective of the present study was the analysis of efficacy and safety of palifermin in children undergoing auto-HSCT. PATIENTS AND METHODS: This matched-pair analysis study included 62 pediatric patients undergoing first auto-HSCT receiving palifermin on a compassionate-use basis (study group, n=31) or not (control group, n=31). RESULTS: Palifermin decreased the incidence of severe (grade 3-4 WHO) oral mucositis (p=0.041), length of hospitalization (p=0.047) and contributed to the shorter duration of oral mucositis (p=0.035) and lower incidence of clinically or microbiologically documented infections (p=0.038). There were no differences between groups in opioid use, neutrophil and platelet recovery, TPN use and gastrointestinal hemorrhage. CONCLUSION: Palifermin decreases the incidence and severity of oral mucositis in children undergoing autologous HSCT. Copyright
BACKGROUND:Keratinocyte growth factor (palifermin) is used for prevention of mucositis in adults following autologous and allogeneic hematopoietic stem cell transplantation (HSCT). It is known that palifermin decreases length of initial hospital stay, mean number of days of total parenteral nutrition (TPN) and the use of opioids for pain control in oral mucositis in adults. There are limited data evaluating palifermin use in children following autologous HSCT. AIM: The objective of the present study was the analysis of efficacy and safety of palifermin in children undergoing auto-HSCT. PATIENTS AND METHODS: This matched-pair analysis study included 62 pediatric patients undergoing first auto-HSCT receiving palifermin on a compassionate-use basis (study group, n=31) or not (control group, n=31). RESULTS: Palifermin decreased the incidence of severe (grade 3-4 WHO) oral mucositis (p=0.041), length of hospitalization (p=0.047) and contributed to the shorter duration of oral mucositis (p=0.035) and lower incidence of clinically or microbiologically documented infections (p=0.038). There were no differences between groups in opioid use, neutrophil and platelet recovery, TPN use and gastrointestinal hemorrhage. CONCLUSION: Palifermin decreases the incidence and severity of oral mucositis in children undergoing autologous HSCT. Copyright
Authors: Wanessa Miranda-Silva; Wagner Gomes-Silva; Yehuda Zadik; Noam Yarom; Abdul Rahman Al-Azri; Catherine H L Hong; Anura Ariyawardana; Deborah P Saunders; M Elvira Correa; Praveen R Arany; Joanne Bowen; Karis Kin Fong Cheng; Wim J E Tissing; Paolo Bossi; Sharon Elad Journal: Support Care Cancer Date: 2020-11-06 Impact factor: 3.603
Authors: Richard M Logan; Abdul Rahman Al-Azri; Paolo Bossi; Andrea M Stringer; Jamie K Joy; Yoshihiko Soga; Vinisha Ranna; Anusha Vaddi; Judith E Raber-Durlacher; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2020-02-21 Impact factor: 3.603
Authors: Wael Saber; Patricia Steinert; Mei-Jie Zhang; Min Chen; Andrea Pope; Armand Keating; John R Wingard; Karen Ballen; Patrick Stiff; Miguel-Angel Perales; Stephen Forman; Richard Champlin; Amelia Langston; Mattias Rudebeck; Mary Horowitz Journal: Transplant Cell Ther Date: 2021-07-02